Tag: <span>r&d</span>

From the Publisher: Regulations, Freedoms, and Money

First, I’m still dying to learn what the regulations are that are keeping American businesses from expanding their operations and hiring people. We keep hearing that the government has to illuminate regulations that are killing jobs, but I just can’t determine what these are. Surely the biopharmaceutical industry isn’t suggesting that it regulate itself while asking the government to protect it from litigation if something goes wrong. And I can’t believe that workplace safety or child labor laws must be abolished. So in this regard, I’ll just have to keep searching until things make sense, or I find they were never meant to…

Read MoreFrom the Publisher: Regulations, Freedoms, and Money

Biologics Production

biologics biopharmaceuticals biotech industry biotech workforce corporate structure divestments grow the market r&d research and development

From the Editor-in-Chief: Building Businesses and Developing Strategic Partnerships

Biologics Production

biologics biopharmaceuticals building businesses entrepreneurship innovation m&a mergers and acquisitions r&d research and development small organizations strategic partnerships

From the Editor-in-Chief: Innovative Small Companies

While I could be deluding myself with wishful thinking, I may be seeing the “new normal” evolving for the biotech industry. The “new normal” may very well be that the mass closing of R&D facilities and the cancellation of major programs is freeing up the CSOs and other entrepreneurs who will start their own companies…

Read MoreFrom the Editor-in-Chief: Innovative Small Companies

Biologics Production

biologics biopharmaceuticals entrepreneurship innovation m&a mergers and acquisitions r&d research and development small organizations

Patent Exhaustion: A Tireless Limit on Patent Rights

Technology-dependent industries such as biotechnology, nanotechnology, and digital signal processing rely heavily on patent law to secure protection for innovation and ensure returns adequate to sustain costly research and development programs. It can be a daunting task to stay current with patent law in the United States, and then throughout the world, the challenges increase exponentially. A case in point is the US, where significant patent law changes brought by the America Invents Act in 2011 are now being implemented. Beyond the revised US patent statute, seemingly lurking in the weeds, is the common law, also known as case or precedent law. One common law doctrine that can exert powerful influence over patent rights and economic behavior is the doctrine of patent exhaustion. In February 2013, the Supreme Court heard arguments in an especially relevant patent exhaustion case involving genetically modified plant seed via viral vector. The article will touch on this case and then move backward in time to review several historic court judgments that have played an integral part in shaping current interpretation of the law. Lastly, Bowman will be revisited…

Read MorePatent Exhaustion: A Tireless Limit on Patent Rights

Biologics Production

america invests act biotech digital signal processing gmo innovation nanotechnology patent exhaustion patent limits patent protection patent statutes r&d viral vector